Insulet (NASDAQ:PODD) Given New $388.00 Price Target at The Goldman Sachs Group

Insulet (NASDAQ:PODD) had its price target upped by stock analysts at The Goldman Sachs Group from $375.00 to $388.00 in a report released on Friday,MarketScreener reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s target price would indicate a potential upside of 21.32% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Wolfe Research increased their target price on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday. Canaccord Genuity Group upped their target price on Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research note on Friday. Leerink Partners boosted their price objective on Insulet from $355.00 to $385.00 and gave the company an “outperform” rating in a report on Friday. Jefferies Financial Group upped their price objective on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Truist Financial boosted their target price on shares of Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $371.38.

Insulet Price Performance

Insulet stock opened at $319.82 on Friday. Insulet has a 52-week low of $230.05 and a 52-week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm’s fifty day moving average is $325.06 and its 200 day moving average is $309.86. The company has a market cap of $22.51 billion, a price-to-earnings ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s revenue was up 29.9% on a year-over-year basis. During the same quarter last year, the business posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts forecast that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC increased its holdings in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the period. Zions Bancorporation National Association UT acquired a new stake in Insulet during the 1st quarter valued at approximately $26,000. SouthState Corp lifted its stake in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares during the period. True Wealth Design LLC boosted its holdings in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the last quarter. Finally, Kozak & Associates Inc. acquired a new stake in Insulet during the 2nd quarter worth about $32,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.